Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins

Infectious Agents and Cancer

Volumn 1, Issue 1, 2006, Pages

  Di Bonito, Paola ^a,g   Grasso, Felicia ^a,g   Mochi, Stefania ^a,g   Accardi, Luisa ^a,g   Donà, Maria Gabriella ^a,g   Branca, Margherita ^a,g   Costa, Silvano ^b,g   Mariani, Luciano ^c,g   Agarossi, Alberto ^d,g   Ciotti, Marco ^e,g   Syrjänen, Kari ^f,g   Giorgi, Colomba ^a,g  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g Turku University Hospital ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34248175173     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-1-6     Document Type: Article

References (45)

1. Doorbar J: The papillomavirus life cycle. J Clin Virol 2005, 32:S7-S15.
2. Syrjänen K, Syrjänen S: Papillomavirus Infections in Human Pathology. Chichester: John Wiley & Sons Ltd;; 2000:1-615.
3. Syrjänen S: Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005, 32:S59-66.
4. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88:63-73.
5. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1157-1164.
6. Dillner J: The serological response to papillomaviruses. Semin Cancer Biol 1999, 9:423-430.
7. Stern PL: Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005, 32:S72-S81.
8. Galloway DA: Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003, 3:469-475.
9. Franco EL, Harper DM: Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005, 23:2388-2394.
10. Lehtinen M, Pawlita M, Zumbach K, Lie K, Hakama M, Jellum E, Koskela P, Luostarinen T, Paavonen J, Pukkala E, Sigstad E, Thoresen S, Dillner J: Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 2003, 188:49-55.
11. Branca M, Costa S, Mariani L, Sesti F, Agarossi A, di Carlo A, Galati M, Benedetto A, Ciotti M, Giorgi C, Criscuolo A, Valieri M, Favalli C, Paba P, Santini D, Piccione E, Alderisio M, De Nuzzo M, di Bonito L, Syrjänen K: Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 2004, 25:689-698.
12. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
13. Rezza G, Giuliani M, Branca M, Benedetto A, Migliore G, Garbuglia AR, D'Ubaldo C, Pezzotti P, Cappiello G, Pomponi Formiconi D, Suligoi B, Schiesari A, Ippolito G, Giacomini G: Determinants of squamous intraepithelial lesions (SIL] on Pap smear: the role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group. Eur J Epidemiol 1997, 13:937-943.
14. Cappiello G, Garbuglia AR, Salvi R, Rezza G, Giuliani M, Pezzotti P, Suligoi B, Branca M, Migliore G, Formigoni Pomponi D, D'Ubaldo C, Ippolito G, Giacomini G, Benedetto A: HIV infection increases the risk of squamous intra-epithelial lesions in women with HPV infection: an analysis of HPV genotypes. DIANAIDS Collaborative Study Group. Int J Cancer 1997, 72:982-986.
15. De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N: Detection and genotyping of human papillomavirus in cervical samples from Italian patients. J Med Virol 2005, 75:588-592.
16. Ronco G, Ghisetti V, Segnan N, Snijders PJ, Gillio-Tos A, Meijer CJ, Merletti F, Franceschi S: Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005, 41:297-305.
17. Carozzi FM, Confortini M, Cecchini S, Bisanzi S, Cariaggi MP, Pontenani G, Raspollini MR, Sani C, Zappa M, Ciatto : Triage with human papillomavirus testing of women with cytologic abnormalities prompting referral for colposcopy assessment. Cancer 2005, 105:2-7.
18. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H: Classification of papillomaviruses. Virology 2004, 324:17-27.
19. Hedman K, Lappalainen M, Söderlund M, Hedman L: Avidity of IgG in serodiagnosis of infectious diseases. Rev Med Microbiol 1993, 4:123-129.
20. Nossal GJ: The molecular and cellular basis of affinity maturation in the antibody response. Cell 1992, 68:1-2.
21. Gray JJ: Avidity of EBV VCA-specific IgG antibodies: distinction between recent primary infection, past infection and reactivation. J Virol Methods 1995, 52:95-104.
22. Eggers M, Bader U, Enders G: Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol 2000, 60:324-330.
23. Pannuti CS, Morello RJ, Moraes JC, Curti SP, Afonso AM, Camargo MC, Souza VA: Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the Sao Paulo epidemic 1997. Clin Diagn Lab Immunol 2004, 11:119-122.
24. Suligoi B, Massi M, Galli C, Sciandra M, Di Sora F, Pezzotti P, Recchia O, Montella F, Sinicco A, Rezza G: Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003, 32:424-428.
25. Roque-Afonso AM, Grangeot-Keros L, Roquebert B, Desbois D, Poveda JD, Mackiewicz V, Dussaix E: Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus. J Clin Microbiol 2004, 42:5121-5124.
26. Munoz FX, Bosch X, Castellsague M, Diaz S, de Sanjose D, Hammouda Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278-285.
27. Di Bonito P, Mochi S, Gro MC, Fortini D, Giorgi C: Organization of the M genomic segment of Toscana phlebovirus. J Gen Virol 1997, 78:77-81.
28. Di Bonito P, Nicoletti L, Mochi S, Accardi L, Marchi A, Giorgi C: Immunological characterization of Toscana virus proteins. Arch Virol 1999, 144:1947-1960.
29. Ciufolini MG, Fiorentini C, Di Bonito P, Mochi S, Giorgi C: Detection of Toscana virus-specific immunoglobulins G and M by an enzyme-linked immunosorbent assay based on recombinant viral nucleoprotein. J Clin Microbiol 1999, 37:2010-2012.
30. Carattoli A, Di Bonito P, Grasso F, Giorgi C, Blasi F, Niedrig M, Cassone A: Recombinant protein-based ELISA and immunocytochemical assay for the diagnosis of SARS. J Med Virol 2005, 76:137-142.
31. Gaberc-Porekar V, Menart V: Potential for Using Histidine Tags in Purification of Proteins at Large Scale. Chemical Engineering & Technology 2005, 28:1306-13 14.
32. Bacarese-Hamilton T, Ardizzoni A, Gray J, Crisanti A: Protein arrays for serodiagnosis of disease. Methods Mol Biol 2004, 264:271-283.
33. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M: Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005, 51:1845-1853.
34. Pirisi L, Yasumoto S, Feller M, Doniger J, DiPaolo JA: Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J Virol 1987, 61:1061-1066.
35. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullins KB, Erlich HA: Primer-directed enzyme amplification of DNA with thermostable DNA polymerase. Science 1988, 239:487-491.
36. Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM: Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol 1995, 33:901-905.
37. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM: The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells Mol Diagnos Hum Cancer 1989, 7:209-214.
38. Huang LW, Chao SL, Chen PH, Chou HP: Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. J Clin Virol 2004, 29:271-276.
39. National Center for Biotechnology Information [http://www.ncbi. nlm.nih.gov]
40. Franconi R, Di Bonito P, Dibello F, Accardi L, Muller A, Cirilli A, Simeone P, Dona MG, Venuti A, Giorgi C: Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Cancer Res 2002, 62:3654-3658.
41. Franconi R, Massa S, Illiano E, Mullar A, Cirilli A, Accardi L, Di Bonito P, Giorgi C, Venuti A: Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Int J Immunopathol Pharmacol 2006, 19:187-197.
42. Accardi L, Dona MG, Di Bonito P, Giorgi C: Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells, Int J Cancer 2005, 116:564-570.
43. Muller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, Bosch FX, Munoz N, Gissmann L, Shah KV: Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology 1992, 187:508-514.
44. Sehr P, Zumbach K, Pawlita M: A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001, 253:153-162.
45. Grabowska K, Wang X, Jacobsson A, Dillner J: Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. J Immunol Methods 2002, 271:1-15.